ClinicalTrials.Veeva

Menu

Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence (ANASTASIA)

AstraZeneca logo

AstraZeneca

Status

Begins enrollment in 1 month

Conditions

Lung Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT07617636
D133FR00226

Details and patient eligibility

About

Observational cohort study involving individuals of both sexes with a history of smoking, residing in municipalities in the state of Bahia and attended by the mobile unit, with the aim of evaluating the integration of artificial intelligence (AI) in the detection of pulmonary nodules and the prediction of ASCT in high-risk individuals undergoing CT screening.

Full description

The main objective of the study is compare the performance of a Sybil AI tool with the LungRADS classifications assigned by radiologists for the risk stratification of pulmonary nodules. Furthermore, it aims to assess the correlation between the AI-predicted STAS and histopathological confirmation, alongside imaging and AI results. The hypothesis is that the Sybil AI model will demonstrate comparable predictive accuracy and that the features predicted by the AI will correlate with the presence of STAS.

Enrollment

1,500 estimated patients

Sex

All

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Individuals of both sexes, smokers or former smokers for a maximum of 15 years;

    • Smoking history of 20 pack-years or more;
    • Between 50 and 80 years old;
    • Provision of Free and Informed Consent in writing, signed and dated.

Exclusion criteria

  • Individuals who are unable to undergo a CT scan;

    • Individuals who cannot tolerate lying on their back for more than 10 minutes continuously;
    • Individuals who present with symptoms highly suggestive of lung cancer (hemoptysis, chest pain, altered cough pattern, unintentional weight loss greater than 10 kg);
    • Diagnosis of severe heart disease while using multiple medications;
    • Diagnosis of severe lung disease, using multiple medications and/or requiring home oxygen therapy;
    • History of radiation therapy to the chest area;
    • Individuals undergoing cancer evaluation or treatment;
    • Individuals exhibiting signs of respiratory distress (nasal flaring, suprasternal retraction, use of accessory muscles, cyanosis);
    • Pregnancy.

Trial contacts and locations

1

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems